, Tracking Stock Market Picks
Enter Symbol:
Myriad Genetics, Inc. (MYGN) [hlAlert]

down 25.62 %

Myriad Genetics, Inc. (MYGN) rated Buy

Posted on: Wednesday,  Nov 28, 2007  9:25 AM ET by GARP Research

GARP Research rated Buy Myriad Genetics, Inc. (NASDAQ: MYGN) on 11/28/2007, when the stock price was $47.68. Since
then, Myriad Genetics, Inc. has lost 25.63% as of 01/21/2016's recent price of $35.46.
If you would have followed this GARP Research's recommendation on MYGN, you would have lost 25.62% of your investment in 2976 days.

Myriad Genetics, Inc. uses gene-based medicine to develop therapeutic and molecular diagnostic products. They employ a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease. They have integrated these technologies using bioinformatics and robotics systems to conduct their research efforts on a high-throughput basis. This has enabled them to identify numerous proteins as targets for new drugs and molecular diagnostic tests.

We are long term investors and all of our recommendations are driven by a single investment philosophy. Whereas most investment research firms build their coverage around industry sectors or corporate finance interests, we simply focus on finding high-quality stocks that we consider to be attractively priced and have the potential to materially appreciate over a two to three year timeframe. All of our recommendations must meet specific criteria of our defined investment philosophy incorporating elements of growth, quality and control of risk. Importantly, we have a multi-year performance record which we believe validates our methodology and points to the thoroughness of our work.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/28/2007 9:25 AM Buy
as of 8/27/2015
1 Week up  14.60 %
1 Month up  2.10 %
3 Months up  3.80 %
1 YTD up  69.01 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy